NextCure Advances Two ADC Programs with Q2 2026 Data Readout Expected for CDH6-Targeted Therapy
核心洞察
NextCure reports Phase 1 dose escalation data for its novel CDH6 (搜索)-targeted ADC SIM0505 is expected in Q2 2026, focusing on gynecological cancers (搜索) including platinum-resistant ovarian cancer (搜索).
The company's second ADC program, LNCB74 targeting B7-H4 (搜索), has expanded into higher dose cohorts with proof-of-concept data now delayed to the second half of 2026 to accommodate enrollment.
NextCure maintains a strong financial position with approximately $41.8 million in cash and securities as of December 31, 2025, providing runway into the first half of 2027.
NextCure, Inc. (NASDAQ: NXTC) provided updates on its two antibody drug conjugate (ADC) programs, announcing expected Phase 1 data readouts and reporting a preliminary cash position of approximately $41.8 million as of December 31, 2025. The clinical-stage biopharmaceutical company is developing novel therapies to treat cancer patients who do not respond to current treatments.
SIM0505 CDH6 ADC Progresses Toward Q2 2026 Data Release
SIM0505, a novel ADC directed to cadherin-6 (CDH6 (搜索)), is designed to target cancers where CDH6 is overexpressed while showing limited expression in healthy tissues. The therapy features a proprietary topoisomerase 1 inhibitor (TOPOi) payload, engineered for broad anti-tumor activity, fast systemic clearance and an improved potential therapeutic window.
Data from the Phase 1 open-label dose escalation study (NCT06792552) are anticipated to be presented in the second quarter of 2026, including results from patients in both the United States and China. The study is evaluating SIM0505 in patients with advanced solid tumors (搜索), with a focus on gynecological cancers (搜索) and particular emphasis on platinum-resistant ovarian cancer (搜索).
NextCure is expanding its clinical infrastructure by adding clinical sites and increasing SIM0505 clinical drug supply in anticipation of initiating dose optimization in the first half of 2026. The company holds global rights for SIM0505, excluding China, Hong Kong, Macau, and Taiwan, which are retained by Simcere Zaiming (搜索).
LNCB74 B7-H4 ADC Enters Higher Dose Cohorts
The company's second ADC program, LNCB74, targets B7-H4 (搜索), which is overexpressed in several cancers with limited expression in healthy tissues. LNCB74 incorporates a proprietary tumor-selective cleavable linker and a tubulin inhibitor monomethyl auristatin E (MMAE) payload.
Dosing has commenced in higher dose cohorts for the ongoing open-label Phase 1 dose escalation study (NCT06774963) following a November 2025 protocol amendment. The higher dose cohorts will prioritize patients with high B7-H4 (搜索) expression in breast and gynecological cancers (搜索), while now including adenoid cystic carcinoma (搜索) type 1.
However, proof-of-concept data, previously anticipated in the first half of 2026, has been delayed to accommodate enrollment challenges. NextCure now expects to provide a trial progress update in the second half of 2026. The company shares global co-development rights for LNCB74 with LigaChem Biosciences (搜索) Inc through a 50-50 cost share arrangement.
Financial Position Supports Operations Through 2027
NextCure reported preliminary cash, cash equivalents and marketable securities of approximately $41.8 million as of December 31, 2025. These preliminary financial results are unaudited and subject to adjustment. The company expects its current financial resources will be sufficient to fund planned operating expenses and capital expenditures into the first half of 2027.
The financial runway provides NextCure with the resources needed to advance both ADC programs through their respective Phase 1 studies and potentially into dose optimization phases. This funding timeline aligns with the company's anticipated data readouts and clinical milestones for both SIM0505 and LNCB74 programs.